Highest-materiality recent filing
XBiotech CEO John Simard retires; CSO Sushma Shivaswamy named interim CEO
John Simard retired as CEO/President effective Dec 8, 2025; continues as Chairman.
XBiotech enters new employment agreement with CEO John Simard; $1.25M salary, $4.53M bonus baseline
Base salary unchanged at $1.25M; annual bonus baseline set at $4.53M for 2025, both inflation-adjusted annually.
XBiotech enters $10M convertible loan from CEO to fund new R&D facility
$10M loan from CEO John Simard at 8% simple interest, secured by real estate and cash.
XBiotech declares special cash dividend of $2.50 per share ($75M total)
Extraordinary cash dividend of approx $2.50/share, aggregate up to $75M.
On March 27, 2025, W. Thorpe McKenzie informed the Board of Directors (the “Board”) of XBiotech Inc. (the “Company”) via letter of his decision to retire from the Board, effective immediately.
Queena Han, whose employment as Vice President, Finance and Human Resource ended on February 3, 2023.
On February 10, 2023, Angela Hu, who presently serves as the Financial Controller of XBiotech Inc. (the “Company”), assumed the role as the Company’s principal financial officer and principal accounting officer.
Max materiality 0.70 · Median 0.40 · Most common event leadership